The HER2-Directed Antibody-Drug Conjugate DHES0815A in Advanced and/or Metastatic Breast Cancer: Preclinical Characterization and Phase I Trial Results

Researchers reported a dose-escalation study in patients with HER2-positive metastatic breast cancer, with the primary objective of evaluating the safety and tolerability of DHES0815A and secondary objectives of characterizing the pharmacokinetics, objective response rate, duration of response, and formation of anti-DHES0815A antibodies.